Metraipolis › archive › dc_fa337e288adc

Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study — Europe PMC PMID:41798184

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41798184
DOI: 10.3389/fendo.2026.1781048
License (as archived): solo-consultazione
Archived: 2026-11-05T14:53:56.966Z
SHA-256 of the archived text: 19f2c87ce12041d9793c442a46261f967aa0fcc3d0764a83bb406cd2a578cb97
Stable URL of this page: https://metraipolis.com/documento/dc_fa337e288adc

How to cite

Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study — Europe PMC PMID:41798184 — Europe PMC (en), https://europepmc.org/article/MED/41798184 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fa337e288adc (Metraipolis archive dc_fa337e288adc, sha256 19f2c87ce12041d9793c442a46261f967aa0fcc3d0764a83bb406cd2a578cb97)

BibTeX

@misc{dcfa337e288adc,
  title = {Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study — Europe PMC PMID:41798184},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41798184},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fa337e288adc; sha256 19f2c87ce12041d9793c442a46261f967aa0fcc3d0764a83bb406cd2a578cb97},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41798184. Agents can read the archived copy with the MCP tool read_document.